U.S. Markets open in 7 hrs 28 mins
  • S&P Futures

    3,448.25
    -1.00 (-0.03%)
     
  • Dow Futures

    28,264.00
    -4.00 (-0.01%)
     
  • Nasdaq Futures

    11,652.75
    +3.00 (+0.03%)
     
  • Russell 2000 Futures

    1,631.70
    +1.10 (+0.07%)
     
  • Crude Oil

    40.45
    -0.19 (-0.47%)
     
  • Gold

    1,907.40
    +2.80 (+0.15%)
     
  • Silver

    24.74
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1806
    -0.0020 (-0.1653%)
     
  • 10-Yr Bond

    0.8480
    0.0000 (0.00%)
     
  • Vix

    28.11
    -0.54 (-1.88%)
     
  • GBP/USD

    1.3058
    -0.0022 (-0.1658%)
     
  • USD/JPY

    104.7100
    -0.1300 (-0.1240%)
     
  • BTC-USD

    12,978.53
    +11.80 (+0.09%)
     
  • CMC Crypto 200

    262.05
    +5.95 (+2.32%)
     
  • FTSE 100

    5,785.65
    +9.15 (+0.16%)
     
  • Nikkei 225

    23,567.69
    +93.42 (+0.40%)
     

PRA Health Sciences: Q2 Earnings Insights

Benzinga Insights
·1 min read

Shares of PRA Health Sciences (NASDAQ:PRAH) rose 1.24% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 29.51% year over year to $0.86, which beat the estimate of $0.82.

Revenue of $729,891,000 decreased by 4.38% from the same period last year, which beat the estimate of $716,720,000.

Guidance

PRA Health Sciences Lowers FY2020 Adj EPS Guidance from $5.77-5.97 to $4.35-4.55 vs $4.31 Est; Lowers FY2020 Sales Guidance from $3.23B-3.36B to $3.07B-3.13B vs $3.07B Est

Technicals

52-week high: $113.31

View more earnings on PRAH

52-week low: $58.67

Price action over last quarter: Up 25.57%

Company Overview

PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.